#BEGIN_DRUGCARD DB01705

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H16N8

# Chemical_IUPAC_Name:
{amino[2-({5-[amino(iminiumyl)methyl]-1,3-benzodiazol-2-yl}methyl)-1,3-benzodiazol-5-yl]methylidene}azanium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Bis(5-Amidino-Benzimidazolyl)Methane

# HET_ID:
BAB

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1705

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
332.3625

# Molecular_Weight_Mono:
332.149792552

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1C1S

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.03

# Predicted_LogS:
-4.5

# Predicted_Water_Solubility:
1.35e-02 g/l

# Primary_Accession_No:
DB01705

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
2386

# PubChem_Substance_ID:
46505413

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00620

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=[NH2+])c1ccc2nc(Cc3nc4ccc(cc4n3)C(N)=[NH2+])nc2c1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:25 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PRSS1

# Drug_Target_1_GenBank_ID_Gene:
M22612

# Drug_Target_1_GenBank_ID_Protein:
521216

# Drug_Target_1_GeneCard_ID:
PRSS1

# Drug_Target_1_Gene_Name:
PRSS1

# Drug_Target_1_Gene_Sequence:
>744 bp
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA

# Drug_Target_1_General_Function:
Involved in protease activity

# Drug_Target_1_General_References:
10204851	Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le Bodic L: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet. 1999 Mar;36(3):228-32.
10381903	Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999 Jul;117(1):7-10.
10930381	Teich N, Ockenga J, Hoffmeister A, Manns M, Mossner J, Keim V: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology. 2000 Aug;119(2):461-5.
11788572	Pfutzer R, Myers E, Applebaum-Shapiro S, Finch R, Ellis I, Neoptolemos J, Kant JA, Whitcomb DC: Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002 Feb;50(2):271-2.
2598466	Kimland M, Russick C, Marks WH, Borgstrom A: Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta. 1989 Sep 15;184(1):31-46.
3011602	Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 1986;41(2-3):305-10.
8683601	Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC: Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol. 1996 Jun 28;259(5):995-1010.
8841182	Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996 Oct;14(2):141-5.
9322498	Gorry MC, Gabbaizedeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997 Oct;113(4):1063-8.
9633818	Teich N, Mossner J, Keim V: Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mutat. 1998;12(1):39-43.

# Drug_Target_1_HGNC_ID:
HGNC:9475

# Drug_Target_1_HPRD_ID:
02039

# Drug_Target_1_ID:
3176

# Drug_Target_1_Locus:
7q32-qter|7q34

# Drug_Target_1_Molecular_Weight:
26558

# Drug_Target_1_Name:
Trypsin-1

# Drug_Target_1_Number_of_Residues:
247

# Drug_Target_1_PDB_ID:
1TRN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_1_Protein_Sequence:
>Trypsin-1 precursor
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS

# Drug_Target_1_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_1_Signals:
1-15

# Drug_Target_1_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_1_SwissProt_ID:
P07477

# Drug_Target_1_SwissProt_Name:
TRY1_HUMAN

# Drug_Target_1_Synonyms:
Cationic trypsinogen
EC 3.4.21.4
Serine protease 1
Trypsin I
Trypsin-1 precursor

# Drug_Target_1_Theoretical_pI:
6.48

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M81186

# Drug_Target_2_GenBank_ID_Protein:
144735

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
botB

# Drug_Target_2_Gene_Sequence:
>3876 bp
ATGCCAGTTACAATAAATAATTTTAATTATAATGATCCTATTGATAATAATAATATTATT
ATGATGGAGCCTCCATTTGCGAGAGGTACGGGGAGATATTATAAAGCTTTTAAAATCACA
GATCGTATTTGGATAATACCGGAAAGATATACTTTTGGATATAAACCTGAGGATTTTAAT
AAAAGTTCCGGTATTTTTAATAGAGATGTTTGTGAATATTATGATCCAGATTACTTAAAT
ACTAATGATAAAAAGAATATATTTTTACAAACAATGATCAAGTTATTTAATAGAATCAAA
TCAAAACCATTGGGTGAAAAGTTATTAGAGATGATTATAAATGGTATACCTTATCTTGGA
GATAGACGTGTTCCACTCGAAGAGTTTAACACAAACATTGCTAGTGTAACTGTTAATAAA
TTAATCAGTAATCCAGGAGAAGTGGAGCGAAAAAAAGGTATTTTCGCAAATTTAATAATA
TTTGGACCTGGGCCAGTTTTAAATGAAAATGAGACTATAGATATAGGTATACAAAATCAT
TTTGCATCAAGGGAAGGCTTCGGGGGTATAATGCAAATGAAGTTTTGCCCAGAATATGTA
AGCGTATTTAATAATGTTCAAGAAAACAAAGGCGCAAGTATATTTAATAGACGTGGATAT
TTTTCAGATCCAGCCTTGATATTAATGCATGAACTTATACATGTTTTACATGGATTATAT
GGCATTAAAGTAGATGATTTACCAATTGTACCAAATGAAAAAAAATTTTTTATGCAATCT
ACAGATGCTATACAGGCAGAAGAACTATATACATTTGGAGGACAAGATCCCAGCATCATA
ACTCCTTCTACGGATAAAAGTATCTATGATAAAGTTTTGCAAAATTTTAGAGGGATAGTT
GATAGACTTAACAAGGTTTTAGTTTGCATATCAGATCCTAACATTAATATTAATATATAT
AAAAATAAATTTAAAGATAAATATAAATTCGTTGAAGATTCTGAGGGAAAATATAGTATA
GATGTAGAAAGTTTTGATAAATTATATAAAAGCTTAATGTTTGGTTTTACAGAAACTAAT
ATAGCAGAAAATTATAAAATAAAAACTAGAGCTTCTTATTTTAGTGATTCCTTACCACCA
GTAAAAATAAAAAATTTATTAGATAATGAAATCTATACTATAGAGGAAGGGTTTAATATA
TCTGATAAAGATATGGAAAAAGAATATAGAGGTCAGAATAAAGCTATAAATAAACAAGCT
TATGAAGAAATTAGCAAGGAGCATTTGGCTGTATATAAGATACAAATGTGTAAAAGTGTT
AAAGCTCCAGGAATATGTATTGATGTTGATAATGAAGATTTGTTCTTTATAGCTGATAAA
AATAGTTTTTCAGATGATTTATCTAAAAACGAAAGAATAGAATATAATACACAGAGTAAT
TATATAGAAAATGACTTCCCTATAAATGAATTAATTTTAGATACTGATTTAATAAGTAAA
ATAGAATTACCAAGTGAAAATACAGAATCACTTACTGATTTTAATGTAGATGTTCCAGTA
TATGAAAAACAACCCGCTATAAAAAAAATTTTTACAGATGAAAATACCATCTTTCAATAT
TTATACTCTCAGACATTTCCTCTAGATATAAGAGATATAAGTTTAACATCTTCATTTGAT
GATGCATTATTATTTTCTAACAAAGTTTATTCATTTTTTTCTATGGATTATATTAAAACT
GCTAATAAAGTGGTAGAAGCAGGATTATTTGCAGGTTGGGTGAAACAGATAGTAAATGAT
TTTGTAATCGAAGCTAATAAAAGCAATACTATGGATAAAATTGCAGATATATCTCTAATT
GTTCCTTATATAGGATTAGCTTTAAATGTAGGAAATGAAACAGCTAAAGGAAATTTTGAA
AATGCTTTTGAGATTGCAGGAGCCAGTATTCTACTAGAATTTATACCAGAACTTTTAATA
CCTGTAGTTGGAGCCTTTTTATTAGAATCATATATTGACAATAAAAATAAAATTATTAAA
ACAATAGATAATGCTTTAACTAAAAGAAATGAAAAATGGAGTGATATGTACGGATTAATA
GTAGCGCAATGGCTCTCAACAGTTAATACTCAATTTTATACAATAAAAGAGGGAATGTAT
AAGGCTTTAAATTATCAAGCACAAGCATTGGAAGAAATAATAAAATACAGATATAATATA
TATTCTGAAAAAGAAAAGTCAAATATTAACATCGATTTTAATGATATAAATTCTAAACTT
AATGAGGGTATTAACCAAGCTATAGATAATATAAATAATTTTATAAATGGATGTTCTGTA
TCATATTTAATGAAAAAAATGATTCCATTAGCTGTAGAAAAATTACTAGACTTTGATAAT
ACTCTCAAAAAAAATTTGTTAAATTATATAGATGAAAATAAATTATATTTGATTGGAAGT
GCAGAATATGAAAAATCAAAAGTAAATAAATACTTGAAAACCATTATGCCGTTTGATCTT
TCAATATATACCAATGATACAATACTAATAGAAATGTTTAATAAATATAATAGCGAAATT
TTAAATAATATTATCTTAAATTTAAGATATAAGGATAATAATTTAATAGATTTATCAGGA
TATGGGGCAAAGGTAGAGGTATATGATGGAGTCGAGCTTAATGATAAAAATCAATTTAAA
TTAACTAGTTCAGCAAATAGTAAGATTAGAGTGACTCAAAATCAGAATATCATATTTAAT
AGTGTGTTCCTTGATTTTAGCGTTAGCTTTTGGATAAGAATACCTAAATATAAGAATGAT
GGTATACAAAATTATATTCATAATGAATATACAATAATTAATTGTATGAAAAATAATTCG
GGCTGGAAAATATCTATTAGGGGTAATAGGATAATATGGACTTTAATTGATATAAATGGA
AAAACCAAATCGGTATTTTTTGAATATAACATAAGAGAAGATATATCAGAGTATATAAAT
AGATGGTTTTTTGTAACTATTACTAATAATTTGAATAACGCTAAAATTTATATTAATGGT
AAGCTAGAATCAAATACAGATATTAAAGATATAAGAGAAGTTATTGCTAATGGTGAAATA
ATATTTAAATTAGATGGTGATATAGATAGAACACAATTTATTTGGATGAAATATTTCAGT
ATTTTTAATACGGAATTAAGTCAATCAAATATTGAAGAAAGATATAAAATTCAATCATAT
AGCGAATATTTAAAAGATTTTTGGGGAAATCCTTTAATGTACAATAAAGAATATTATATG
TTTAATGCGGGGAATAAAAATTCATATATTAAACTAAAGAAAGATTCACCTGTAGGTGAA
ATTTTAACACGTAGCAAATATAATCAAAATTCTAAATATATAAATTATAGAGATTTATAT
ATTGGAGAAAAATTTATTATAAGAAGAAAGTCAAATTCTCAATCTATAAATGATGATATA
GTTAGAAAAGAAGATTATATATATCTAGATTTTTTTAATTTAAATCAAGAGTGGAGAGTA
TATACCTATAAATATTTTAAGAAAGAGGAAGAAAAATTGTTTTTAGCTCCTATAAGTGAT
TCTGATGAGTTTTACAATACTATACAAATAAAAGAATATGATGAACAGCCAACATATAGT
TGTCAGTTGCTTTTTAAAAAAGATGAAGAAAGTACTGATGAGATAGGATTGATTGGTATT
CATCGTTTCTACGAATCTGGAATTGTATTTGAAGAGTATAAAGATTATTTTTGTATAAGT
AAATGGTACTTAAAAGAGGTAAAAAGGAAACCATATAATTTAAAATTGGGATGTAATTGG
CAGTTTATTCCTAAAGATGAAGGGTGGACTGAATAA

# Drug_Target_2_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_2_General_References:
1331807	Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992 Oct 29;359(6398):832-5.
1429690	Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C: Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992 Nov 25;267(33):23479-83.
1514783	Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP: Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol. 1992 Aug;58(8):2345-54.
3139097	Dasgupta BR, Datta A: Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin. Biochimie. 1988 Jun;70(6):811-7.
3888113	Schmidt JJ, Sathyamoorthy V, DasGupta BR: Partial amino acid sequences of botulinum neurotoxins types B and E. Arch Biochem Biophys. 1985 May 1;238(2):544-8.
8408542	Campbell KD, Collins MD, East AK: Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. J Clin Microbiol. 1993 Sep;31(9):2255-62.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2324

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
150804

# Drug_Target_2_Name:
Botulinum neurotoxin type B

# Drug_Target_2_Number_of_Residues:
1291

# Drug_Target_2_PDB_ID:
1S0G

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01742	Peptidase_M27
PF07951	Toxin_R_bind_C
PF07952	Toxin_trans
PF07953	Toxin_R_bind_N

# Drug_Target_2_Protein_Sequence:
>Botulinum neurotoxin type B precursor
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE

# Drug_Target_2_Reaction:
Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevin (also known as neuronal vesicle-associated membrane protein, VAMP), synaptosome-associated protein of 25 kDa (SNAP25) or syntaxin. No detected action on small molecule substrates

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2

# Drug_Target_2_SwissProt_ID:
P10844

# Drug_Target_2_SwissProt_Name:
BXB_CLOBO

# Drug_Target_2_Synonyms:
BoNT/B
Bontoxilysin-B
Botulinum neurotoxin type B precursor
EC 3.4.24.69

# Drug_Target_2_Theoretical_pI:
4.97

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01705
